![]() |
Israeli biotechnology company NurExone is developing an innovative treatment based on exosomes, tiny particles naturally released by the body's cells to transport messages and biological materials between them.
The company loads these particles with a molecular payload designed to stimulate the nervous system to repair damaged connections, with the hope of helping people who have lost the ability to move or see regain some of their lost functions.
The technology builds on research conducted by scientists from the Technion – Israel Institute of Technology and Tel Aviv University.
In experiments involving rats whose spinal cords had been completely severed, the animals were able to walk again following treatment. The company's CEO, Dr. Lior Shaltiel, described the results as "very strong proof of concept."
One particularly promising aspect of the treatment is its method of administration: it was delivered through nasal drops, without the need for surgery.
However, the treatment has not yet been tested in humans. The company plans to begin human trials in the near future.

Comments